Literature DB >> 11449745

Using cost and financing instruments for economic evaluation of substance abuse treatment services.

H J Salomé1, M T French.   

Abstract

Standardized economic evaluation instruments are an important tool in the analysis of change and performance of addiction treatment. Nevertheless, compared to other health care sectors, economic evaluation of addiction treatment is still rare. The present paper proposes two comprehensive economic evaluation instruments that are methodologically sound and that meet the objectives of comprehensiveness, standardization, and comparability. The Drug Abuse Treatment Cost Analysis Program (DATCAP) can be used to estimate the economic cost of treatment services; the Drug Abuse Treatment Financing Analysis Program (DATFin) is a companion instrument and analyzes the complexity and change of treatment financing. This paper outlines the contents of each instrument and, for illustrative purposes, presents results from several case studies. Suggestions for updates and enhancements for each instrument are also discussed.

Mesh:

Year:  2001        PMID: 11449745     DOI: 10.1007/978-0-306-47193-3_14

Source DB:  PubMed          Journal:  Recent Dev Alcohol        ISSN: 0738-422X


  2 in total

1.  Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.

Authors:  Michael T French; Helena J Salomé; Jody L Sindelar; A Thomas McLellan
Journal:  Health Serv Res       Date:  2002-04       Impact factor: 3.402

2.  A randomized trial to identify accurate and cost-effective fidelity measurement methods for cognitive-behavioral therapy: project FACTS study protocol.

Authors:  Rinad S Beidas; Johanna Catherine Maclean; Jessica Fishman; Shannon Dorsey; Sonja K Schoenwald; David S Mandell; Judy A Shea; Bryce D McLeod; Michael T French; Aaron Hogue; Danielle R Adams; Adina Lieberman; Emily M Becker-Haimes; Steven C Marcus
Journal:  BMC Psychiatry       Date:  2016-09-15       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.